Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Bombesin receptor antagonists with potential in sexual dysfunction

July 5, 2002

Merck presents new alpha1A-adrenoceptor antagonists for BPH

July 2, 2002

Fujisawa claims beta3-adrenoceptor agonists for urinary incontinence, etc.

June 28, 2002

Nymox files NX-1207 IND in benign prostatic hyperplasia

June 27, 2002

Lilly Icos continues to develop PDE5 inhibitors

June 27, 2002

Recent patent covers new PDE5 inhibitors designed at Lilly Icos

June 21, 2002

Trospium completes phase III trial in overactive bladder

June 20, 2002

Senju patents novel Na+/Ca2+ exchange inhibitors

June 19, 2002

Boehringer Ingelheim claims new agents for urinary incontinence

June 18, 2002

Shire files for approval of Fosrenol in Canada

June 11, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...